-
JAAD Case Reports Sep 2022
PubMed: 35875513
DOI: 10.1016/j.jdcr.2022.07.017 -
Journal of the European Academy of... Dec 2022
Topics: Humans; Pityriasis Lichenoides; COVID-19 Vaccines; BNT162 Vaccine; COVID-19; SARS-CoV-2; Vaccines
PubMed: 35841285
DOI: 10.1111/jdv.18418 -
Dermatologic Therapy Aug 2022Various adverse effects particularly cutaneous manifestations associated with different COVID-19 vaccines have been observed in practice. The aim of our study was to...
Various adverse effects particularly cutaneous manifestations associated with different COVID-19 vaccines have been observed in practice. The aim of our study was to evaluate all patients who presented to our tertiary center with skin manifestations following COVID-19 vaccines injection from September to December 2021. All patients with skin manifestation within 30 days or less following COVID-19 vaccination were enrolled in our case-series. All cases included in our study were diagnosed based on clinical and/or histopathological evaluation and all other possible differential diagnoses were ruled out. Twenty-five individuals including 16 (64%) males and 9 (36%) females with the mean age of 47 ± 17.62 years (range 18-91) were enrolled in our study. Twenty-two (88%) patients developed lesions after Sinopharm vaccine injection and 3 (12%) cases manifested lesions after the AstraZeneca vaccine. Six (24%) patients developed new-onset lichen planus (LP) and 1 (4%) patient manifested LP flare-up. Two (8%) individuals developed psoriasis and 1 (4%) case showed psoriasis exacerbation. One (4%) patient developed new-onset pemphigus vulgaris (PV) and 1 (4%) case experienced a flare of PV lesions. One (4%) patient manifested pityriasis lichenoides et varioliformis acuta (PLEVA) flare-up. Other new-onset cases were as follows: toxic epidermal necrolysis (TEN) (n = 1, 4%), bullous pemphigoid (BP) (n = 2, 8%), alopecia areata (AA) (n = 2, 8%), pytriasis rosea (n = 1, 4%), herpes zoster (n = 1, 4%), cutaneous small vessel vasculitis (n = 1, 4%), erythema multiform (EM) and urticaria (n = 3, 12%), and morphea (n = 1, 4%). Physicians should be aware of the possible side effects especially cutaneous manifestations associated with COVID-19 vaccines.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Vaccines; Female; Humans; Male; Middle Aged; Pemphigus; Pityriasis Lichenoides; Psoriasis; Vaccination; Young Adult
PubMed: 35716105
DOI: 10.1111/dth.15651 -
Journal of the European Academy of... Oct 2022
Topics: Aged; COVID-19; COVID-19 Vaccines; Humans; Male; Pityriasis Lichenoides
PubMed: 35617206
DOI: 10.1111/jdv.18269 -
Dermatology and Therapy May 2022Parapsoriasis is an uncommon inflammatory skin disease characterized by chronic patches that may be resistant to therapy. It was primarily introduced and classified... (Review)
Review
Parapsoriasis is an uncommon inflammatory skin disease characterized by chronic patches that may be resistant to therapy. It was primarily introduced and classified 120 years ago, and the original classification incorporated parapsoriasis and pityriasis lichenoides under the umbrella term parapsoriasis. After a major change in classification, parapsoriasis now exclusively refers to small plaque parapsoriasis (SPP) and large plaque parapsoriasis (LPP). However, debates still frequently occur regarding various nomenclatures and classifications used by different authors. Moreover, parapsoriasis may progress to overt cutaneous lymphoma, most commonly mycosis fungoides (MF), and it is very difficult to distinguish these two conditions despite modern histologic and molecular testing techniques.As parapsoriasis is a rare disease, there is a lack of studies and clinical guidelines to assist physicians in clinical practice. In our comprehensive review, we review several aspects of parapsoriasis, from the history of nomenclature and classification, clinical characteristics, immunohistopathology, and advanced molecular techniques for the diagnosis of this condition, to the most current treatments. We also propose a scheme for distinguishing parapsoriasis from early-stage MF in this review.
PubMed: 35426607
DOI: 10.1007/s13555-022-00716-y -
Drug-induced pityriasis lichenoides from infliximab in a patient with juvenile idiopathic arthritis.JAAD Case Reports May 2022
PubMed: 35402674
DOI: 10.1016/j.jdcr.2022.02.017 -
Dermatologic Therapy Jun 2022
Topics: COVID-19; Humans; Pityriasis Lichenoides; RNA, Messenger; Vaccination
PubMed: 35286000
DOI: 10.1111/dth.15445 -
Journal of the European Academy of... Jun 2022
Topics: COVID-19; Chronic Disease; Humans; Pityriasis Lichenoides; Recurrence; SARS-CoV-2; Vaccination
PubMed: 35184341
DOI: 10.1111/jdv.18024 -
JAAD Case Reports Mar 2022
PubMed: 35141383
DOI: 10.1016/j.jdcr.2021.12.018 -
JAAD Case Reports Feb 2022
PubMed: 34926748
DOI: 10.1016/j.jdcr.2021.11.021